Jpmorgan Chase & CO Alx Oncology Holdings Inc Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Alx Oncology Holdings Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 40,425 shares of ALXO stock, worth $60,233. This represents 0.0% of its overall portfolio holdings.

Number of Shares

40,425

Previous 41,897 3.51%

Holding current value

$60,233

Previous $467,000 47.97%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$5.84 - $17.56 $8,596 - $25,848	-1,472 Reduced 3.51%	40,425 $243,000
Q1 2024 May 10, 2024	SELL	$10.95 - $16.79 $62,261 - $95,467	-5,686 Reduced 11.95%	41,897 $467,000
Q4 2023 Feb 12, 2024	BUY	$4.81 - $15.38 $124,328 - $397,542	25,848 Added 118.92%	47,583 $708,000
Q3 2023 Nov 14, 2023	BUY	$4.19 - $7.35 $13,320 - $23,365	3,179 Added 17.13%	21,735 $104,000
Q2 2023 Aug 11, 2023	BUY	$4.37 - $9.56 $3,273 - $7,160	749 Added 4.21%	18,556 $139,000
Q1 2023 May 18, 2023	BUY	$4.52 - $11.71 $74,277 - $192,430	16,433 Added 1196.0%	17,807 $80,000
Q1 2023 May 11, 2023	SELL	$4.52 - $11.71 $54,429 - $141,011	-12,042 Reduced 89.76%	1,374 $6,000
Q4 2022 Feb 13, 2023	SELL	$9.51 - $12.95 $11,079 - $15,086	-1,165 Reduced 7.99%	13,416 $151,000
Q3 2022 Nov 14, 2022	BUY	$8.23 - $15.14 $9,489 - $17,456	1,153 Added 8.59%	14,581 $140,000
Q2 2022 Aug 11, 2022	SELL	$5.89 - $19.46 $34,215 - $113,043	-5,809 Reduced 30.2%	13,428 $109,000
Q1 2022 May 11, 2022	BUY	$13.65 - $22.06 $46,642 - $75,379	3,417 Added 21.6%	19,237 $326,000
Q4 2021 Feb 10, 2022	BUY	$21.49 - $74.4 $17,020 - $58,924	792 Added 5.27%	15,820 $340,000
Q3 2021 Nov 12, 2021	BUY	$52.51 - $80.91 $789,120 - $1.22 Million	15,028 New	15,028 $1.11 Million

Others Institutions Holding ALXO

# of Institutions

120

Shares Held

41.2M

Call Options Held

518K

Put Options Held

142K

View Full List

About ALX ONCOLOGY HOLDINGS INC

Ticker ALXO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,747,100
Market Cap $60.7M
Description
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hod...

More about ALXO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Alx Oncology Holdings Inc Transaction History